New combo therapy aims to control bladder cancer without surgery
NCT ID NCT06434350
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether combining the drug enfortumab vedotin with radiation therapy can help control locally advanced bladder cancer. About 41 adults with urothelial carcinoma of the bladder will receive the drug by IV along with radiation. The main goal is to check safety and side effects, and to see if the combination helps manage the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Enfortumab vedotin (a drug given by IV) and radiation therapy
- What this could lead to
- If it works, this could offer a new treatment option to control locally advanced bladder cancer without needing surgery.
- What could go wrong
- This is a very early Phase 1/2 trial with only 41 people, so results may not apply widely. The drug can cause side effects like nerve damage or skin reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.